Table 4. Baseline demographics, laboratory findings, and chief features of the 52 cases.
| Data available (%) * | Median (IQR) | |
|---|---|---|
| Age (years) | 40/52 (76.9) | 63.5 (49.3–72.5) |
| Sex | 51/52 (98.1) | |
| Male | 15/51 (29.4) | |
| Female | 36/51 (70.6) | |
| Past medical history | 19/52 (36.5) | |
| RA | 4/19 (21.1) | |
| SLE | 4/19 (21.1) | |
| SjS | 3/19 (15.8) | |
| Others | 8/19 (42.2) | |
| Lymphadenopathy | 29/52 (55.8) | |
| Regional | 11/29 (37.9) | |
| Generalized | 18/29 (62.1) | |
| Clinical diagnosis | 42/52 (80.8) | |
| RA | 11/42 (26.2) | |
| SLE | 11/42 (26.2) | |
| AIHA | 9/42 (21.4) | |
| SjS | 2/42 (4.8) | |
| Cryoglobulinemia | 2/42 (4.8) | |
| Drug-induced (Sulfasalazine, ST) | 2/42 (4.8) | |
| Others | 5/42 (11.9) | |
| Initial treatment | 30/52 (57.7) | |
| Corticosteroid monotherapy | 14/30 (46.7) | |
| Cyclophosphamide, vincristine, and prednisone | 5/30 (16.7) | |
| Corticosteroid with non-steroidal immunosuppressant | 3/30 (10.0) | |
| Others | 8/30 (26.7) |
Abbreviations: AIHA: autoimmune hemolytic anemia; SjS: Sjögren syndrome; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; Trimethoprim/sulfamethoxazole